Diabetes. 2005;54(7):2188-2197.

Diabetic retinopathy progresses from mild nonproliferative abnormalities, characterized by increased vascular permeability, to moderate and severe nonproliferative diabetic retinopathy (NPDR ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...

The first and earlier stage is called nonproliferative retinopathy ... unlike type 1 diabetes where it is very rare to have severe diabetic retinopathy within the first 5 years after diagnosis ...

Four-year visual outcomes in the protocol w randomized trial of intravitreous aflibercept for prevention of vision-threatening complications of diabetic retinopathy. JAMA. 2023;329:376-385. 2. Brown ...

Women with chronic diabetes should undergo a retinopathy screening early in pregnancy. Anti-VEGF drug labels recommend against use in pregnant women. KOLOA, Hawaii — Patients with diabetic ...

Aims: The aim of this study was to report the development or progression of tractional retinal detachment (TRD) after the injection of intravitreal bevacizumab (Avastin) used as an adjuvant to ...

Abstract: Diabetic retinopathy (DR) is a severe complication of diabetes that affects the retinal structures and can lead to significant visual impairment or even blindness. Early diagnosis is crucial ...

Jan. 9, 2025 — Hydroclimate whiplash -- rapid swings between intensely wet and dangerously dry weather -- has already increased globally due to climate change, with further large increases ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.

Kaiser shared data from the phase 1 HELIOS trial that showed stability or improvement in diabetic retinopathy at 1 year after treatment with the implant. Patients also saw improvements in diabetic ...